OXFORD: Sensyne Health plc, the British clinical AI technology company, announced it has entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health.
Lord (Paul) Drayson, CEO of Sensyne Health, said: “New techniques using artificial intelligence and machine learning have the potential to improve patient care and accelerate medical research, however they also require the development of new methods to validate them. As a leading company in the field of Clinical AI we are delighted to be working with the UK’s regulatory agency on this vital project.”
Edited by Kazim Rizvi